

## Product Update:

**empagliflozin plus metformin 5mg/85mg, 5mg/1000mg, 12.5mg/850mg, 12.5mg/1000mg film-coated tablets (Synjardy®) SMC No. (1092/15)**  
**Boehringer Ingelheim Ltd.**

4 September 2015

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in Scotland. The advice is summarised as follows:

**ADVICE:** following an abbreviated submission

**empagliflozin/metformin (Synjardy®)** is accepted for restricted use within NHS Scotland.

**Indication under review:** in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control;

- in patients inadequately controlled on their maximally tolerated dose of metformin alone
- in patients inadequately controlled with metformin in combination with other glucose-lowering medicinal products, including insulin
- in patients already being treated with the combination of empagliflozin and metformin as separate tablets.

**SMC restriction:**

- for use in patients for whom this fixed dose combination of empagliflozin and metformin is considered appropriate.
- for use as dual therapy (empagliflozin and metformin) when a sulphonylurea is inappropriate.

Empagliflozin/metformin (Synjardy®) has the potential to reduce the pill burden at no additional cost.

### **Advice context:**

*No part of this advice may be used without the whole of the advice being quoted in full.*

*This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.*

*This assessment is based on data submitted by the applicant company up to and including 28 May 2015.*

**Chairman, Scottish Medicines Consortium**